Latest news for Beroni Gr (OTC:BNIGF) Stock

Beroni Group Ltd is an Australia based company engaged in the sale of smoking control product (NicoBloc), air purifier, healthcare products and supplements, cosmetics and stem-cell therapies. It has organized its business into four core business areas: cell therapies, developing new anticancer drugs, an e-commerce platform for pharmaceutical and healthcare products, and detection & diagnosis of infectious diseases. Its operating segment includes Nicobloc, Fogibloc air purifier, Olansi water filter, Health supplements, Cosmetic products, Viral diagnostic kits, and Technical advisory service. Geographically, it operates in China and Japan. The highest revenue is generated from the Nicobloc segment through the China region.

News

Health Care

Movers & Shakers

Small Cap

Events

Global

Markets

Trading Ideas

ETFs

General

BNIGF

EMMA

LXRP

MBRX

NRIFF

ORXOY

RDHL

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.

In addition to causing chaos in markets and economies around the world, the spread of the COVID-19 coronavirus has put the biotechnology and health care industries under the microscope.

With The World In The Midst Of A Pandemic, Attention Turns To Life Sciences

Beroni Group Ltd

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Jefferies analyst David Stanton downgraded the rating for Mesoblast Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) from Buy to Hold. Mesoblast shares closed at $14.63 on Friday. <a href="https://www.benzinga.com/quote/MESO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>William Blair analyst Sami Corwin downgraded Applied Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLT#NASDAQ">APLT</a>) from Outperform to Market Perform. Applied Therapeutics shares closed at $0.8801 on Friday. <a href="https://www.benzinga.com/quote/APLT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>BTIG analyst Thomas Catherwood downgraded the rating for Innovative Industrial Properties, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IIPR#NYSE">IIPR</a>) from Buy to Neutral. NCR Atleos shares closed at $73.66 on Friday. <a href="https://www.benzinga.com/quote/IIPR/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying MESO stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="590" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23104327/image-193-1024x590.png" alt="" class="wp-image-704457" style="width:578px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23104327/image-193-1024x590.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23104327/image-193-300x173.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23104327/image-193-768x442.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23104327/image-193.png 1085w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42616196/jim-cramer-likes-walmart-recommends-buying-this-very-very-good-financial-stock">Jim Cramer Likes Walmart, Recommends Buying This &#8216;Very, Very Good&#8217; Financial Stock</a></li>
</ul>

Downgrades

Analyst Ratings

APLT

IIPR

MESO

This Mesoblast Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Monday

Options

SOUN

SoundHound AI Option Alert: Jan 3 $21 Calls Sweep (21) Near The Ask: 483 @ $2.401 Vs 834 OI; Ref=$20.83

Shares of autonomous driving technology leader Pony AI Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>) <a href="https://www.benzinga.com/24/11/42228142/symbotic-unusual-machines-vci-global-pony-ai-tesla-why-these-5-stocks-are-on-investors-radars-today">debuted on Nasdaq in November</a>.
The Fremont, California-based company has the largest fleet of Level 4 autonomous mobility, offering robotaxi and robotruck services across China, according to Goldman Sachs.
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/635ac86c2048c300015a37cd/allen-chang">Analyst Allen Chang</a> initiated coverage of Pony AI with a Buy rating and a price target of $19.60.
The Pony AI Thesis: The company is the first to operate completely driverless robotaxis in four tier-1 cities in China, having obtained regulatory permits for providing robotaxi services to the general public, Chang said in the initiation note.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
While competition is a concern, it will take time for other companies to develop a vehicle that does not need any safety drivers to offer a better riding experience to passengers versus traditional taxis, the analyst stated. 
"Besides, it also takes time to accumulate autonomous driving mileage / track record to earn the operation license from governments," he added.
"Pony AI continues to make progress on robotaxi commercialization, and we expect a revenue CAGR of 27% in 2024-27E on ramp up of its robotaxi fleet operation and start of licenses fee contribution from robotaxi solutions, then a 158% CAGR over 2027-30E with accelerated scale expansion, driving EBITDA and NI to turn positive in 2030E," Chang further wrote.
Price Action: Shares of Pony AI had risen by 4.48% to $13.75 at the time of publication on Monday.
Read More: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42230178/chinas-robotaxi-firm-looks-to-diversify-supply-chain-as-nasdaq-debut-sees-disappointment-amid-global-competition-with-tesla-waymo-and-amazon">China&#8217;s Robotaxi Firm Pony AI Looks To Diversify Supply Chain After Nasdaq Debut, Growing Competition With Tesla, Waymo, And Amazon</a></li>
</ul>
Image: Shutterstock

Analyst Color

Long Ideas

Initiation

Movers

PONY

Pony AI Speeds Past Competitors, Commercializes Fully Driverless Vehicles

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Scotiabank analyst Sung Ji Nam initiated coverage on Thermo Fisher Scientific Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Sector Perform rating and announced a price target of $605. Thermo Fisher Scientific shares closed at $524.05 on Friday. <a href="https://www.benzinga.com/quote/TMO/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Goldman Sachs analyst Allen Chang initiated coverage on Pony AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>) with a Buy rating and announced a price target of $19.6. Pony AI shares closed at $13.16 on Friday. See how other analysts view this stock.</li>
<li>Compass Point analyst Dominick Gabriele initiated coverage on NCR Atleos Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NATL#NYSE">NATL</a>) with a Buy rating and announced a price target of $57. NCR Atleos shares closed at $32.33 on Friday. <a href="https://www.benzinga.com/quote/NATL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>D. Boral Capital analyst Jason Kolbert initiated coverage on Omeros Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) with a Buy rating and announced a price target of $36. Omeros shares closed at $10.31 on Friday. <a href="https://www.benzinga.com/quote/OMER/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Alliance Global Partners analyst Aaron Grey initiated coverage on Worksport Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKSP#NASDAQ">WKSP</a>) with a Buy rating and announced a price target of $2. Worksport shares closed at $0.8465 on Thursday. <a href="https://www.benzinga.com/quote/WKSP/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying OMER stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="573" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23103558/image-192-1024x573.png" alt="" class="wp-image-704444" style="width:622px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23103558/image-192-1024x573.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23103558/image-192-300x168.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23103558/image-192-768x430.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23103558/image-192.png 1102w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42616196/jim-cramer-likes-walmart-recommends-buying-this-very-very-good-financial-stock">Jim Cramer Likes Walmart, Recommends Buying This &#8216;Very, Very Good&#8217; Financial Stock</a></li>
</ul>

NATL

OMER

WKSP

This Omeros Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

RELI

Reliance Global Shares Resume Trade

Reliance Global Shares Halted On Circuit Breaker To The Upside, Stock Now Up 290.8%

DRCT

Direct Digital Shares Resume Trade Then Again Halted On Circuit Breaker To The Upside, Stock Now Up 183.6%

<a href="https://www.theinformation.com/articles/openai-nvidia-and-their-rivals-expand-ai-turf-wars" title="https://www.theinformation.com/articles/openai-nvidia-and-their-rivals-expand-ai-turf-wars">https://www.theinformation.com/articles/openai-nvidia-and-their-rivals-expand-ai-turf-wars</a>
&nbsp;
Nvidia Aims To Rival AWS With Cloud Services And Software Business; OpenAI Develops Server Chips And Browser To Reduce Nvidia And Google Dependence; Elon Musk Builds Massive Supercomputing Cluster For Conversational AI; Major Tech Firms Race To Expand AI Hardware And Software Stacks Amid Intensifying Competition And Efforts To Reduce Supplier Reliance

MSFT

NVDA

'OpenAI, Nvidia And Their Rivals Expand AI Turf Wars' - The Information

Investors with a lot of money to spend have taken a bullish stance on Boeing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with BA, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 29 uncommon options trades for Boeing.
This isn't normal.
The overall sentiment of these big-money traders is split between 55% bullish and 37%, bearish.
Out of all of the special options we uncovered, 6 are puts, for a total amount of $323,005, and 23 are calls, for a total amount of $880,234.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $140.0 to $200.0 for Boeing over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Boeing's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Boeing's significant trades, within a strike price range of $140.0 to $200.0, over the past month.
<h3>Boeing 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734967838_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$36.5</td>
<td>$30.9</td>
<td>$30.9</td>
<td>$200.00</td>
<td>$154.5K</td>
<td>1.7K</td>
<td align="right">0</td>
</tr>
<tr>
<td>BA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/03/25</td>
<td>$1.55</td>
<td>$1.55</td>
<td>$1.55</td>
<td>$185.00</td>
<td>$113.9K</td>
<td>1.2K</td>
<td align="right">821</td>
</tr>
<tr>
<td>BA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$10.8</td>
<td>$10.55</td>
<td>$10.55</td>
<td>$170.00</td>
<td>$52.7K</td>
<td>11.1K</td>
<td align="right">85</td>
</tr>
<tr>
<td>BA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$4.3</td>
<td>$4.25</td>
<td>$4.25</td>
<td>$150.00</td>
<td>$50.1K</td>
<td>2.8K</td>
<td align="right">812</td>
</tr>
<tr>
<td>BA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$48.2</td>
<td>$47.7</td>
<td>$48.2</td>
<td>$140.00</td>
<td>$48.2K</td>
<td>103</td>
<td align="right">10</td>
</tr>
</tbody>
</table>

<h3>About Boeing</h3>
Boeing is a major aerospace and defense firm. It operates in three segments: commercial airplanes; defense, space, and security; and Global services. Boeing's commercial airplanes segment competes with Airbus in the production of aircraft that can carry more than 130 passengers. Boeing's defense, space, and security segment competes with Lockheed, Northrop, and several other firms to create military aircraft, satellites, and weaponry. Global services provides aftermarket support to airlines.
In light of the recent options history for Boeing, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of Boeing</h3>
<ul>
<li>With a volume of 1,879,101, the price of BA is down -0.28% at $176.86. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 37 days.</li>
</ul>
<h3>What Analysts Are Saying About Boeing</h3>
In the last month, 1 experts released ratings on this stock with an average target price of $190.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from JP Morgan has decided to maintain their Overweight rating on Boeing, which currently sits at a price target of $190. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Boeing with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Check Out What Whales Are Doing With Boeing

Direct Digital Holdings Shares Halted To The Upside; Stock Now Up 143.64%

Investors with a lot of money to spend have taken a bearish stance on ServiceNow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with NOW, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 14 uncommon options trades for ServiceNow.
This isn't normal.
The overall sentiment of these big-money traders is split between 21% bullish and 64%, bearish.
Out of all of the special options we uncovered, 3 are puts, for a total amount of $130,910, and 11 are calls, for a total amount of $1,080,381.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $230.0 to $1140.0 for ServiceNow over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
In today's trading context, the average open interest for options of ServiceNow stands at 47.88, with a total volume reaching 98.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in ServiceNow, situated within the strike price corridor from $230.0 to $1140.0, throughout the last 30 days.
<h3>ServiceNow Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734967832_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$280.6</td>
<td>$272.5</td>
<td>$272.5</td>
<td>$850.00</td>
<td>$545.0K</td>
<td align="right">49</td>
<td align="right">20</td>
</tr>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$861.7</td>
<td>$848.5</td>
<td>$855.58</td>
<td>$230.00</td>
<td>$85.5K</td>
<td align="right">12</td>
<td align="right">2</td>
</tr>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$862.1</td>
<td>$855.3</td>
<td>$855.3</td>
<td>$230.00</td>
<td>$85.5K</td>
<td align="right">12</td>
<td align="right">1</td>
</tr>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$399.8</td>
<td>$393.8</td>
<td>$397.93</td>
<td>$700.00</td>
<td>$79.5K</td>
<td align="right">11</td>
<td align="right">2</td>
</tr>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$321.8</td>
<td>$315.6</td>
<td>$315.6</td>
<td>$860.00</td>
<td>$63.1K</td>
<td align="right">80</td>
<td align="right">0</td>
</tr>
</tbody>
</table>

<h3>About ServiceNow</h3>
ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management, expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service.
In light of the recent options history for ServiceNow, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>ServiceNow's Current Market Status</h3>
<ul>
<li>Trading volume stands at 86,368, with NOW's price down by -1.13%, positioned at $1078.87.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 30 days.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for ServiceNow, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Check Out What Whales Are Doing With NOW

Investors with a lot of money to spend have taken a bullish stance on Exxon Mobil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with XOM, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 9 uncommon options trades for Exxon Mobil.
This isn't normal.
The overall sentiment of these big-money traders is split between 22% bullish and 22%, bearish.
Out of all of the special options we uncovered, 4 are puts, for a total amount of $141,045, and 5 are calls, for a total amount of $265,371.
<h3>Expected Price Movements</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $42.5 and $115.0 for Exxon Mobil, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Exxon Mobil's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Exxon Mobil's whale activity within a strike price range from $42.5 to $115.0 in the last 30 days. 
<h3>Exxon Mobil Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734967826_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>XOM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$5.5</td>
<td>$5.35</td>
<td>$5.5</td>
<td>$105.00</td>
<td>$100.1K</td>
<td>2.6K</td>
<td align="right">186</td>
</tr>
<tr>
<td>XOM</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$65.25</td>
<td>$61.1</td>
<td>$63.13</td>
<td>$42.50</td>
<td>$63.1K</td>
<td>3</td>
<td align="right">0</td>
</tr>
<tr>
<td>XOM</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$7.0</td>
<td>$6.9</td>
<td>$6.95</td>
<td>$110.00</td>
<td>$49.3K</td>
<td>16.0K</td>
<td align="right">58</td>
</tr>
<tr>
<td>XOM</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$8.1</td>
<td>$7.95</td>
<td>$8.02</td>
<td>$100.00</td>
<td>$40.1K</td>
<td>837</td>
<td align="right">50</td>
</tr>
<tr>
<td>XOM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$7.05</td>
<td>$6.9</td>
<td>$6.92</td>
<td>$110.00</td>
<td>$34.6K</td>
<td>16.0K</td>
<td align="right">52</td>
</tr>
</tbody>
</table>

<h3>About Exxon Mobil</h3>
ExxonMobil is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2023, it produced 2.4 million barrels of liquids and 7.7 billion cubic feet of natural gas per day. At the end of 2023, reserves were 16.9 billion barrels of oil equivalent, 66% of which were liquids. The company is one of the world's largest refiners with a total global refining capacity of 4.5 million barrels of oil per day and is one of the world's largest manufacturers of commodity and specialty chemicals.
Following our analysis of the options activities associated with Exxon Mobil, we pivot to a closer look at the company's own performance.
<h3>Where Is Exxon Mobil Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 1,980,999, with XOM's price down by -0.4%, positioned at $105.45.</li>
<li>RSI indicators show the stock to be may be oversold.</li>
<li>Earnings announcement expected in 39 days.</li>
</ul>
<h3>Expert Opinions on Exxon Mobil</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $123.2.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from RBC Capital downgraded its action to Sector Perform with a price target of $115. 
&#x2A; An analyst from RBC Capital persists with their Sector Perform rating on Exxon Mobil, maintaining a target price of $115. 
&#x2A; An analyst from Piper Sandler persists with their Overweight rating on Exxon Mobil, maintaining a target price of $127. 
&#x2A; Consistent in their evaluation, an analyst from JP Morgan keeps a Overweight rating on Exxon Mobil with a target price of $125. 
&#x2A; Maintaining their stance, an analyst from Mizuho continues to hold a Neutral rating for Exxon Mobil, targeting a price of $134. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Exxon Mobil, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Smart Money Is Betting Big In XOM Options

Imperial Oil (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IMO#AMEX">IMO</a>) has outperformed the market over the past 5 years by 5.62% on an annualized basis producing an average annual return of 18.39%. Currently, Imperial Oil has a market capitalization of $32.81 billion. 
Buying $1000 In IMO: If an investor had bought $1000 of IMO stock 5 years ago, it would be worth $2,314.74 today based on a price of $61.23 for IMO at the time of writing.
<h3>Imperial Oil's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734967823_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today

Kevin O&#8217;Leary, the well-known entrepreneur and <a href="https://www.benzinga.com/news/24/12/42559810/people-think-kevin-oleary-is-the-mean-shark-but-he-says-im-not-mean-i-just-tell-the-truth-to-keep-families-from-going-broke">investor from Shark Tank</a>, has weighed in on why so many tech CEOs and business leaders are suddenly cozying up to President-elect Donald Trump. During a recent <a href="https://www.youtube.com/watch?v=oML1qbX1_uM">interview</a> on Fox &amp; Friends, O&#8217;Leary said it's not just about Trump's corporate tax policies – the real reason is deregulation.
For context, Trump's policies, such as maintaining the 21% corporate tax rate, undoubtedly appeal to businesses. However, according to O'Leary, the bigger draw is Trump's commitment to cutting federal red tape, making it easier for businesses to grow and operate without constant legal battles and administrative hurdles.
Don't Miss:
<ul>
<li>Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/1milsaved"> The percentage may shock you</a>.</li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
</ul>
O&#8217;Leary pointed out that federal deregulation under Trump's administration is particularly attractive to companies involved in <a href="https://www.benzinga.com/calendars/m-a">mergers and acquisitions</a>. He noted that Trump will "cool off all these pursuits and change many of the administrative rules that make it harder to get things done."
In simple terms, businesses see Trump as someone who will make it easier for them to operate without worrying about constant interference from regulators. That's a huge selling point for companies looking to expand or innovate.
<h2 class="wp-block-heading">CEOs See Trump as &#8216;The Guy&#8217;</h2>
O&#8217;Leary was direct about why CEOs are eager to meet with Trump. &#8220;They're not stupid,&#8221; he said. &#8220;They're saying, &#8216;Well, I think I'm going to go suck up with him because he's the guy for sure for the next two years.'&#8221;
See Also: The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a>
This isn't just about tech leaders like Mark Zuckerberg or Jeff Bezos. O&#8217;Leary said leaders from various industries – and even other countries – are lining up to meet with Trump, recognizing his influence and power in shaping business policy.
<h2 class="wp-block-heading">Donations for Trump&#8217;s Inauguration</h2>
Mark Zuckerberg and <a href="https://www.benzinga.com/tech/24/12/42479253/jeff-bezos-amazon-pledges-1-million-to-trumps-inaugural-event-following-in-the-footsteps-of-mark-zuckerberg-and-meta">Jeff Bezos have each contributed $1 million</a> through their companies, Meta Platforms and Amazon. OpenAI CEO Sam Altman is joining them, making a <a href="https://www.benzinga.com/news/management/24/12/42485193/sam-altman-to-donate-1m-to-trumps-inauguration-fund-following-zuckerberg-bezos-eager-to-support">personal donation of $1 million</a>. Perhaps surprisingly, the trading platform Robinhood has donated $2 million.
O&#8217;Leary highlighted that these donations represent a shift in attitude among business leaders. This is about aligning with Trump's vision for the economy and acknowledging his dominance in shaping the future of policy.&nbsp;
Trending: It&#8217;s no wonder Jeff Bezos holds over $70 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a>
Altman, for instance, has publicly praised Trump's commitment to advancing AI infrastructure, a sentiment echoed by other tech leaders. &#8220;President Donald Trump will lead our country into the age of AI and I am eager to support his efforts to ensure America stays ahead,&#8221; he said.
The President-elect&#8217;s ability to remove regulatory roadblocks has made him an attractive ally for business leaders, regardless of their personal opinions about him.
<h2 class="wp-block-heading">Why Deregulation Can Be Harmful</h2>
While <a href="https://www.benzinga.com/markets/equities/24/11/42383725/trump-administrations-deregulation-efforts-to-lift-energy-oil-and-gas-sectors-ai-frenzy-to-aid-faang-stocks-and-nvidia-says-fintech-insider">deregulation is a win for businesses</a>, it can also result in significant drawbacks. <a href="https://www.imf.org/external/pubs/ft/wp/2013/wp13247.pdf">Reduced oversight</a> often opens the door to harmful practices, such as environmental damage, compromised safety standards and unfair labor practices. It can also mean fewer consumer protections, which could let businesses focus more on profits than on doing what's right for people.
Read Next:
<ul>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
</ul>

Kevin O'Leary Says Deregulation Is The Real Reason Everybody Is 'Sucking Up To Trump Now,' Not Lower Taxes

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Raymond James analyst Buck Horne upgraded the rating for Weyerhaeuser Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WY#NYSE">WY</a>) from Market Perform to Outperform and announced a $32 price target. Weyerhaeuser shares closed at $27.50 on Friday. <a href="https://www.benzinga.com/quote/WY/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co. analyst Raghuram Selvaraju upgraded the rating for Aclaris Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) from Neutral to Buy and maintained the price target of $20. Aclaris Therapeutics shares closed at $2.72 on Friday. See how other analysts view this stock.</li>
<li>Piper Sandler analyst Crispin Love upgraded GCM Grosvenor Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCMG#NASDAQ">GCMG</a>) from Neutral to Overweight and raised the price target from $12.5 to $14. GCM Grosvenor shares closed at $11.75 on Friday. <a href="https://www.benzinga.com/quote/GCMG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Raymond James analyst Buck Horne upgraded the rating for PotlatchDeltic Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCH#NASDAQ">PCH</a>) from Market Perform to Outperform and announced a $45 price target. PotlatchDeltic shares closed at $38.75 on Friday. <a href="https://www.benzinga.com/quote/PCH/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying WY stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="592" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23102908/image-191-1024x592.png" alt="" class="wp-image-704426" style="width:637px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23102908/image-191-1024x592.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23102908/image-191-300x173.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23102908/image-191-768x444.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23102908/image-191.png 1078w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42616196/jim-cramer-likes-walmart-recommends-buying-this-very-very-good-financial-stock">Jim Cramer Likes Walmart, Recommends Buying This &#8216;Very, Very Good&#8217; Financial Stock</a></li>
</ul>

Upgrades

Price Target

ACRS

GCMG

This Weyerhaeuser Analyst Turns Bullish; Here Are Top 4 Upgrades For Monday

Rumble Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUM#NASDAQ">RUM</a>) shares are trading higher Monday after the company announced it entered into a definitive agreement for a $775 million strategic investment from <a href="https://www.benzinga.com/24/12/42634166/rumble-stock-soars-on-775-million-investment-from-tether-what-to-know">Tether (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">USDT</a>)</a>.
The Details: Rumble on Friday announced that Tether plans to buy 103.33 million shares of its common stock for $7.50 per share, representing $775 million in gross proceeds. Tether offers the most widely used dollar <a href="https://www.benzinga.com/topic/stablecoins">stablecoin</a> with more than 350 million users. 
Rumble plans to use $250 million of the gross proceeds to support growth initiatives, while the remaining funds will be used for a self-tender offer of up to 70 million Rumble shares at the same price as Tether&#8217;s investment.
Rumble CEO Chris Pavlovski does not intend to sell more than 10 million shares of common stock in the tender offer. He will retain his controlling stake in the company.
&#8220;I could not be more excited about this collaboration with Tether for a number of reasons. First, many people may not realize the incredibly strong connection between the cryptocurrency and free speech communities, which is rooted in a passion for freedom, transparency, and decentralization,&#8221; Pavlovski said.
&#8220;Second, the immediate commitment of adding $250 million in cash to our balance sheet not only confirms the level of support and commitment to a collaboration between our companies, it also fuels our growth initiatives. And, third, this transaction provides an immediate liquidity event for all of our stockholders who elect to participate in the self tender offer.&#8221;
Rumble&#8217;s existing board and governance structure, including Pavlovski&#8217;s super-majority voting control, will remain unchanged following the closing of the transaction. 
Tether will own a minority position in Rumble&#8217;s outstanding common stock, but will not have the right to designate any members of the board. The investment and tender offer are expected to close during the first quarter of 2025. 
Related Link: <a href="https://www.benzinga.com/24/12/42647650/palantir-vs-lockheed-a-tech-fueled-showdown-in-the-850-billion-defense-market">Palantir Vs. Lockheed: A Tech-Fueled Showdown In The $850 Billion Defense Market</a>
RUM Price Action: At the time of writing, Rumble shares were up 79.8% at $12.92, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: Shutterstock.

$USDT

Rumble Stock Is Ripping Higher Monday: What's Going On?

Truist Securities analyst Joon Lee maintains Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Buy and lowers the price target from $550 to $460.

VRTX

Truist Securities Maintains Buy on Vertex Pharmaceuticals, Lowers Price Target to $460

Direct Digital Shares Resume Trade

Direct Digital Shares Halted On Circuit Breaker To The Upside, Stock Now Up 98.2%

Loop Capital analyst Mark Schappel maintains E2open Parent Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETWO#NYSE">ETWO</a>) with a Hold and lowers the price target from $4 to $3.

ETWO

Loop Capital Maintains Hold on E2open Parent Holdings, Lowers Price Target to $3

Beroni Gr

The following post was written and/or published as a collaboration between Benzinga&rsquo;s in-house sponsored content team and a financial partner of Benzinga.

In addition to causing chaos in markets and economies around the world, the spread of the COVID-19 coronavirus has put the biotechnology and health care industries under the microscope.

Suddenly, hundreds of such companies are redirecting resources in an effort to find a vaccine or treatment that could potentially halt the virus&rsquo; spread. This has made the biotech space one of the few hot spots in a historically bad month for stocks.

The shelter-in-place orders in the U.S. and other countries have also made it difficult for many of these companies to communicate directly with investors. This is especially challenging for biotech companies, which are often more communicative with investors than companies in other industries. Expensive drug trial and capital raising cycles, make constant communication with investors essential, according to John Viglotti, senior vice president of corporate services and investor access at OTC Markets.

&ldquo;They are faced with a constant need to raise capital to fund clinical trials, and these clinical trials are not stopping,&rdquo; he said. &ldquo;The life science business is certainly continuing.&rdquo;

In an effort to bridge that gap between investors hungry for information and companies trying to reach them, OTC Markets is hosting the first <a href="https://www.lifesciencesinvestorforum.com/events/event-details/agenda?utm_source=Article&amp;utm_medium=Benzinga&amp;utm_campaign=LSIF%2003262020">Virtual Life Science Investor Forum</a> on March 26. The online-only conference will consist of investor presentations from seven companies in five countries. Some will be giving updates on their COVID-19 treatments.

&ldquo;Certainly with what&rsquo;s going on with the coronavirus pandemic, it just makes it that much more relevant,&rdquo; said Jason Paltrowitz, executive vice president of corporate services at OTC Markets. &ldquo;The public at large is certainly interested in COVID-19, but from an investor perspective there are great opportunities.&rdquo;

According to Viglotti, over 200 life sciences companies have previously participated in virtual investor conferences, making it one of the most popular sectors to participate in the conference series.

&ldquo;It was really done with the realization that there are so many pre-revenue, early stage private life science companies that are just starved for attention,&rdquo; Paltrowitz said of this week&rsquo;s conference. &ldquo;And we thought being able to host a series of virtual conferences would help.&rdquo;

Below is the schedule for the conference. Each presentation is followed by a virtual Q&amp;A session with attendees and is available on demand.

To learn more about attending Thursday&rsquo;s conference, <a href="https://www.lifesciencesinvestorforum.com/events/event-details/agenda?utm_source=Article&amp;utm_medium=Benzinga&amp;utm_campaign=LSIF%2003262020">click here</a>.

9:30 AM ET RedHill Biopharma Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDHL#NASDAQ">RDHL</a>) 
Speaker: Guy Goldberg, Chief Business Officer 
About: RedHill is a specialty biopharmaceutical company focused on gastrointestinal diseases. RedHill has commercial operations in the U.S., with a sales force promoting several gastrointestinal drugs across the U.S., including RedHill&rsquo;s recently FDA approved drug, Talicia&reg;. RedHill also has a robust development pipeline with several late-stage development programs which have successfully completed Phase 3 studies.

10:00 AM ET Nuvo Pharmaceuticals Inc. (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/NRIFF#OTCQX">NRIFF</a>) 
Speakers: Jesse Ledger, President &amp; Chief Executive Officer, and Kelly Demerino, Interim Chief Financial Officer 
About: Nuvo is a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products. The Company targets several therapeutic areas, including pain, allergy and dermatology. The Company&#39;s strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets.

10:30 AM ET Orexo AB (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/ORXOY#OTCQX">ORXOY</a>) 
Speaker: Nikolaj S&oslash;rensen, President &amp; CEO 
About: Orexo develops improved pharmaceuti&shy;cals and digital therapies addressing unmet needs mainly within the growing space of addiction. The products are commercialized by Orexo in the US or via partners worldwide. The main market today is the American market for buprenorphine/naloxone products, where Orexo commercializes its lead product Zubsolv&reg; for treatment of opioid use disor&shy;der.

11:00 AM ET Emmaus Life Sciences, Inc. (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/EMMA#OTCQB">EMMA</a>) 
Speakers: Dr. Yutaka Niihara, Chairman and Chief Executive Officer, and Jay Sherwood 
Chief Financial Officer

About: Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sale of innovative treatments and therapies, including those in the rare and orphan disease categories. Its FDA-approved Endari&reg; (prescription grade L-glutamine oral powder) is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.

11:30 AM ET Moleculin Biotech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBRX#NASDAQ">MBRX</a>) 
Speaker: Walter Klemp, Founder, President, CEO &amp; Chairman 
About: Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly resistant tumors. The Company&#39;s clinical stage drugs are: Annamycin, a Next Generation Anthracycline, designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic cancer and hematologic malignancies, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin is also engaged in preclinical development of additional drug candidates, including additional Immune/Transcription Modulators, as well as compounds capable of Metabolism/Glycosylation Inhibition.

12:00 PM ET Lexaria Bioscience Corp. (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/LXRP#OTCQX">LXRP</a>) 
Speaker: Chris Bunka, CEO 
About: Lexaria Bioscience Corp. is a global innovator in drug delivery platforms. Its patented DehydraTECH&trade; drug delivery technology changes the way API&#39;s enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules. DehydraTECH increases bio-absorption; reduces time of onset; and can reduce drug costs for orally administered bioactive molecules including nicotine, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and other molecules. Lexaria has licensed DehydraTECH to multiple companies for use in various oral application formats, including to a world-leading tobacco producer for the development of smokeless, oral-based nicotine products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and over 60 patents pending worldwide.

12:30 PM ET Beroni Group Ltd. (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/BNIGF#OTCQX">BNIGF</a>) 
Speakers: Jacky Zhang, Chairman and CEO, and Peter Wong, Group CFO 
About: Beroni Group is an international biotechnological company listed on the National Stock Exchange (Australia) with business presence in Australia, China, Japan and the USA. It currently has four core businesses - cell therapies, developing new anti-cancer drugs, e-commerce platform for pharmaceutical and healthcare products, and detection &amp; diagnosis of infectious diseases.

To learn more about attending Thursday&rsquo;s conference, <a href="https://www.lifesciencesinvestorforum.com/events/event-details/agenda?utm_source=Article&amp;utm_medium=Benzinga&amp;utm_campaign=LSIF%2003262020">click here</a>.

Photo by&nbsp;<a href="https://unsplash.com/@thisisengineering?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText">ThisisEngineering RAEng</a>&nbsp;on&nbsp;<a href="https://unsplash.com/s/photos/laboratory?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText">Unsplash</a>

The preceding post was written and/or published as a collaboration between Benzinga&rsquo;s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice.

Comments

Beroni Gr

News

Latest news for Beroni Gr (OTC:BNIGF) Stock

Wednesday, March 25, 2020

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga